[1] Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology, 2003,37:902-908.
[2] Abraldes JG, Albillos A, Ba±Ares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology,2009,136:1651-1658.
[3] 中华医学会肝病学分会. 慢性乙型肝炎防治指南2010年更新版. 中华实验和临床感染病杂志(电子版),2011,05:50-60.
[4] 中华医学会消化病学分会. 中国肝性脑病诊治共识意见(2013年,重庆) . 中国医学前沿杂志(电子版),2014,6:81-93.
[5] Bosch J, Garciapagán JC, Berzigotti A, et al. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis, 2006, 26:348-362.
[6] Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol,2009,8:453-463.
[7] Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology,2013,144:323-332.
[8] Chae YK, Yousaf M, Malecek MK, et al. Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit Discov Med, 2015,20:413.
[9] Graupera M, Zafra C, García H. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl cirrhotic rats. J Hepatol, 2007,46:1040-1046.
[10] Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology, 2007,46:242.
[11] Marrone G, Russo L, Rosado E, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol,2013,58:98.
[12] Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology, 2014,60:679-686. |
